MedTrace Logo

Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension

NCT02145611 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2016-08-16

No results posted yet for this study

Summary

Cardiovascular disease is a major public health problem in our country. Among the causes of cardiovascular diseases are High Blood Pressure (HBP) and Diabetes Mellitus (DM). Type 2 diabetes (DM2) is associated with a twofold risk of cardiovascular disease, and endothelial dysfunction is an early marker of vascular complications. There is evidence of action of glucagon-like peptide 1 (GLP-1) on endothelial cells and vascular smooth muscle. Vildagliptin is a drug used in the treatment of DM2 able to prolong the activity of GLP-1, improving glycemic control and endothelial function.

Objectives: To evaluate the effect of vildagliptin on endothelial function in patients with DM2 and hypertension using the Endo-PAT 2000 device.

Conditions

Interventions

DRUG

Glibenclamide

Glibenclamide

DRUG

Vildagliptin

Vildagliptin

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Dr. José Fernando Vilela-Martin MD PhD

    lead OTHER

Principal Investigators

  • Jose F Vilela-Martin, MD PhD · Fundação Faculdade Regional de Medicina de São José do Rio Preto

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02145611 on ClinicalTrials.gov